Medpace (MEDP) closed at $561.65, down 1.27% from the previous day, underperforming the S&P 500, Dow, and Nasdaq. Analysts anticipate an EPS of $4.18 and revenue of $681.17 million in the upcoming earnings disclosure. Zacks Rank currently rates MEDP as a #2 (Buy).

Looking ahead, Medpace’s valuation metrics include a Forward P/E ratio of 38.45, higher than the industry average. The PEG ratio is 2.15, above the industry average of 1.72. The Medical Services industry has a Zacks Industry Rank of 165, placing it in the bottom 34% of industries.

Zacks is naming its top 10 stocks for 2026, with a history of outperforming the S&P 500. Director of Research Sheraz Mian will reveal these picks on January 5 after combing through 4,400 companies. Don’t miss out on these potential high performers.

Read more at Nasdaq: Why Medpace (MEDP) Dipped More Than Broader Market Today